Extra Glycemic Impacts of GLP-1 Receptor Agonists: Benefits of a Class Effect?
Open Access
- 1 January 2016
- journal article
- research article
- Published by Scientific Research Publishing, Inc. in Open Journal of Endocrine and Metabolic Diseases
- Vol. 06 (01), 43-57
- https://doi.org/10.4236/ojemd.2016.61007
Abstract
GLP-1 receptor agonists are approved for the treatment of type 2 diabetes, and more recently for obesity treatment. The glucagon-like-peptide-1 (GLP-1) is a glucose dependent hormone produced by intestinal cells, which is involved in insulin secretion and glucagon suppression. This hormone controls glucose plasma levels and reduces food intake. Additional effects were reported in slowing gastric emptying and in inducing satiety. In clinical practice, theGLP-1 receptor agonists are associated with significant reductions in glycosylated hemoglobin (HbA1c) and weight loss, despite showing a low risk of hypoglycemia. Beneficial effects have also been observed on blood pressure and lipid profile. The most common side effects associated with GLP-1 receptor agonists are gastro-intestinal motility disorders, such as nausea, vomiting and diarrhea, which are not associated with long-term health risks. Therefore, GLP-1 receptor agonists represent a relevant medication for type 2 diabetes, whose benefits may go far beyond glycemic control.Keywords
This publication has 67 references indexed in Scilit:
- Cardiovascular Biology of the Incretin SystemEndocrine Reviews, 2012
- Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trialsBMJ, 2012
- Glucagon Like Peptide-1 Receptor Expression in the Human Thyroid GlandJournal of Clinical Endocrinology & Metabolism, 2012
- Pancreatitis, Pancreatic, and Thyroid Cancer With Glucagon-Like Peptide-1–Based TherapiesGastroenterology, 2011
- Exenatide once weekly treatment maintained improvements in glycemic control and weight loss over 2 yearsBMC Endocrine Disorders, 2011
- Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetesDiabetes, Obesity and Metabolism, 2011
- Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trialThe Lancet, 2010
- Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)The Lancet, 2009
- Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority studyThe Lancet, 2008
- Incretin-Based Therapies in Type 2 Diabetes MellitusJournal of Clinical Endocrinology & Metabolism, 2008